Our commitment to you just got stronger.
Mayne Pharma releases Doryx® MPC (doxycycline hyclate delayed-release tablets) 120 mg
NEW Doryx MPC is a tetracycline-class antimicrobial indicated as adjunctive therapy for severe acne. The modified polymer coat further delays absorption of doxycycline into the GI tract by 15 minutes resulting in relatively more release of the active drug into the small intestine1. A tetracycline-class antimicrobial indicated as adjunctive therapy for severe acne available in 120 mg dosage strength for precision dosing without multiple tablets or scoring1-3.
To learn more about Doryx MPC please click here.
*The usual dose of oral doxycycline is 240 mg on the first day of treatment (administered 120 mg every 12 hours), followed by a maintenance dose of 120 mg daily. In the management of more severe infections (particularly chronic infections of the urinary tract), 120 mg every 12 hours is recommended.
Mayne Pharma acquires Fabior® (tazarotene) Foam, 0.1% and Sorilux® (calcipotriene) Foam, 0.005% from GSK
Fabior is a retinoid in a topical foam formulation for the treatment of acne vulgaris in patients 12 years of age and older. Fabior Foam is not for oral, ophthalmic, or intravaginal use.
Sorilux contains calcipotriene, a synthetic vitamin D3 analogue. It is indicated for the topical treatment of plaque psoriasis in patients aged 18 years and older. Plaque psoriasis is a chronic, non-contagious, inflammatory skin condition that appears as red patches covered with silvery flakes often found on the elbows, scalp and knees but can also affect other parts of the body.
During the intervening period GSK will continue to distribute Fabior and Sorilux.
For more information on this acquisition, please click here.
Important Safety Information about Doryx® MPC (doxycycline hyclate delayed-release tablets)
Doxycycline is contraindicated in patients who have shown hypersensitivity to any of the tetracyclines. Tetracycline-class drugs, like Doryx® MPC (doxycycline hyclate delayed-release tablets), can cause fetal harm when administered to a pregnant woman. Doryx® MPC should be avoided if possible by nursing mothers, taking into account the importance of the drug to the mother. Doryx® MPC should not be used in children during tooth development (up to the age of 8 years). Concurrent use of tetracycline-class antibiotics with oral contraceptives may reduce their effectiveness.
Please see full prescribing information for Doryx MPC here.
Important Safety Information about Fabior® (tazarotene) Foam
Fabior Foam is contraindicated in pregnancy and may cause fetal harm when administered in pregnant women. Females of childbearing potential should have a negative pregnancy test within two weeks prior to initiating treatment and use an effective method of contraception during treatment.It should be used with caution in patients with a history of local tolerability reactions or local hypersensitivity. Concomitant topical acne therapy should be used with caution because a cumulative irritant effect may occur. Because of increased photosensitivity and risk of sunburn, patients should avoid exposure to sunlight, sunlamps, and weather extremes, and should wear sunscreen daily. The propellant in Fabior Foam is flammable so patients should be instructed to avoid fire, flame, and smoking during and immediately following application. The most common adverse reactions reported at an incidence ≥ 6% are application site irritation, application site dryness, application site erythema, and application site exfoliation.
Please see full prescribing information for Fabior here.
Important Safety Information about Sorilux® (calcipotriene) Foam
The propellant in Sorilux Foam is ﬂammable. Instruct the patient to avoid ﬁre, ﬂame, and smoking during and immediately following application. Sorilux Foam should be used during pregnancy only if the potential beneﬁt justiﬁes the potential risk to the fetus. It is not known whether calcipotriene is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Sorilux Foam is administered to a nursing woman. Safety and effectiveness of Sorilux Foam in pediatric patients less than 18 years of age have not been established. Sorilux Foam has not been evaluated in patients with erythrodermic, exfoliative, or pustular psoriasis. Sorilux Foam is not for oral, ophthalmic, or intravaginal use
Please see full prescribing information for Sorilux here.
To report SUSPECTED ADVERSE REACTIONS, contact Mayne Pharma at 1-844-825-8500 or FDA at 1 800-FDA-1088 or www.fda.gov/medwatch.
Doryx, Fabior, and Sorilux are registered trademarks of Mayne Pharma.
1. Doryx MPC [package insert]. Greenville, NC: Mayne Pharma; 2016. 2. Kircik LH, Bikowski JB. Enteric-coated doxycycline pellets, delayed release, in tablets. Pract Dermatol. 2010;(suppl):5-8. 3. Data on file. Greenville, NC; Mayne Pharma.